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Extracts from Cimicifuga racemosa (CR, synonym Actaea racemosa) have shown eﬃcacy in trials in women with menopausal
symptoms. Yet, dose dependency remains unclear. Therefore, 180 female outpatients with climacteric complaints were treated
for 12 weeks in a randomized, double-blind, placebo-controlled, 3-armed trial (CR extract Ze 450 in 6.5mg or 13.0mg, or
placebo). Primary outcome was the diﬀerence in menopausal symptoms (vasomotor, psychological, and somatic), assessed by
the Kupperman Menopausal Index between baseline and week 12. Secondary eﬃcacy variables were patients’ self-assessments of
general quality of life (QoL), responder rates, and safety. Compared to placebo, patients receiving Ze 450 showed a significant
reduction in the severity of menopausal symptoms in a dose-dependent manner from baseline to endpoint (mean absolute
diﬀerences 17.0 (95% CI 14.65–19.35) score points, P < 0.0001 for 13.0mg; mean absolute diﬀerences 8.47 (95% CI 5.55–11.39)
score points, P = 0.0003 for 6.5mg). QoL and responder rates corresponded with the main endpoint. Changes in menopausal
symptoms and QoL were inversely correlated. Reported adverse events and clinical laboratory testing did not raise safety concerns.
The CR extract Ze 450 is an eﬀective and well-tolerated nonhormonal alternative to hormone treatment for symptom relief in
menopausal women.
1. Introduction
On the one hand, menopause is a normal biological process
marking the transition of the lives of mature women
from a reproductive into a postreproductive phase. On
the other hand the profound physiological changes in the
peri- and postmenopausal period can provoke complaints.
Menopausal changes can lead to vasomotor (e.g., hot flushes,
sweating), psychological/vegetative (e.g., insomnia, nervous-
ness/irritability, depressive event, and palpitation), somatic
(e.g., joint pain), and urogenital/sexual (e.g., libido changes,
dyspareunia, and vaginal dryness) symptoms. They vary in
frequency and severity, are related to lifestyle, demographics
and sociocultural circumstances, and have been well charac-
terized [1–3]. Hot flushes and night sweating are the cardinal
symptoms with highly varying prevalence between 24 to
93% [3–6]. However, the interrelationship of hot flushes and
sweating with other neuropsychological symptoms seems to
diminish QoL in symptomatic menopausal women [7, 8].
Although the role of estrogen appears to be critical
and is underlined by the clinical eﬀects of estrogen or
estrogen/progestin therapy [9, 10], the mechanisms leading
to the development of hot flushes have not been fully
elucidated [11]. Since large epidemiological studies with
long-term hormonal replacement therapy (HRT), such as
the Women’s Health Initiative and the Million Women Study
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[12–15], have shown a small but significantly increased risk
for the development of invasive breast cancer, there is an
increasing interest in nonhormonal treatment modalities for
patients with climacteric symptoms.
Cimicifuga racemosa L. (synonym Actaea racemosa L.,
black cohosh) is a perennial medicinal plant native to North
America where it has been used for centuries in indigenous
medicine for the treatment of various conditions. However,
today’s sole accepted indications are menopause-related neu-
rovegetative and emotional symptoms. Cimicifuga racemosa
(CR) extracts are described in a 2003 monograph of the
European Scientific Cooperative on Phytotherapy (ESCOP)
as a pharmacologically active treatment of climacteric symp-
toms [16] and in the 2010 community herbal monograph
of the Committee on Herbal Medicinal Products of the
European Medicines Agency [17]; a well-established use
status was granted.
The precise mechanism of action of CR is controversial,
with some studies suggesting that it has no estrogenic
eﬀect while others indicate a selective estrogen modulating
eﬀect on some tissues, such as bone [18–20]. In addition,
serotonin-binding properties in the brain may contribute
to its mechanism of action [21, 22]. If indeed CR lacks
estrogenic eﬀects, it would have a beneficial influence on
climacteric vasomotor and psychiatric symptoms without
adversely aﬀecting the development of breast or uterine
tissue tumors or increasing the cardiovascular risk.
Randomized, controlled clinical trials (RCTs) have
shown clinically significant eﬀects of extracts from CR [20,
23–26]; but the results have not been consistent in systematic
reviews [27–29]. The comparability of the trials is diﬃcult
because of diﬀerences in dosing, outcome parameters, rating
scales, and diﬀerent CR extracts used [30]. Nevertheless, a
meta-analysis performed showed the eﬃcacy of extracts from
CR in vasomotor symptoms; but the authors pointed out the
heterogeneity of the trials [31].
Dose-dependent eﬀects of an isopropanolic aqueous CR
extract have been previously investigated by Liske et al.
[25]. Though no placebo or active control treatment was
used in this study, both the low- and high-dose improved
climacteric symptoms compared to baseline values, and no
diﬀerences between the treatments could be demonstrated
in the Kupperman Menopausal Index (KMI) [32]. For the
present study, therefore, placebo treatment was compared
to the dose-dependent eﬀects of the CR extract Ze 450 on
climacteric symptoms.
2. Patients andMethods
For this multicenter, randomized, double-blind, placebo-
controlled, parallel-group trial, 180 female outpatients with
menopausal complaints were included. The study took place
in four outpatient clinics. Patients were randomized to
receive either 13.0mg Ze 450, 6.5mg Ze 450 or placebo for
12 weeks.
The study was performed between March 19, 2002 and
July 23, 2003.
2.1. Ethics. The study protocol was approved by the Ethics
Committee of the Medical Association (Ethik-Kommission
Landesa¨rztekammer Hessen), Frankfurt, Germany, and the
German Federal Institute for Drugs and Medical Devices
(Bundesinstitut fu¨r Arzneimittel und Medizinprodukte
(BfArM)) was informed prior to its start. Conduct was
in accordance with the ICH Guidelines for Good Clinical
Practice and the Declaration of Helsinki. A written informed
consent was obtained from all patients prior to screen-
ing/baseline visit.
2.2. Inclusion/Main Exclusion Criteria. Females (age ≥
40 years) suﬀering from menopausal syndrome with neu-
rovegetative components, which have been stable anamnesti-
cally during the last 2 weeks, and who consulted a physician
for the treatment of symptoms were included. The diagnosis
of menopausal complaints was confirmed by a Climax Score
according to M. Metka and F. H. Fischl. The Climax Score
includes neurovegetative, psychical, and atrophic symptoms.
By using this tool, the diagnosis of menopausal syndrome
was confirmed by the physician. In addition, the baseline
Kupperman Menopausal Index (KMI) was recorded by the
investigator. Patients were excluded due to previous or
current psychological disease that could interfere with their
ability to participate in the study; anamnestic or current
alcohol or drug abuse; concomitant treatment with psy-
chotropic (in particular benzodiazepines, antidepressants,
hypnotics or neuroleptics, tamoxifen, clomifen, and danazol)
or hormonally acting drugs such as hormone replacement
therapy (HRT); hyperthyroidism; malignant tumors; contin-
uous climacteric bleeding and complaints related tomyomas;
patients who have taken another experimental drug within
a 4-week period prior to the trail; pregnancy/lactation;
serious internal disease; previous organ transplantation;
premenopausal women with insuﬃcient contraceptive pro-
tection; hypersensitivity to one of the ingredients of the trial
medication; a body mass index >30.
2.3. Study Medication. A 6.5mg tablet of the (60% v/v)
ethanolic CR extract Ze 450 (from rhizomes and roots of
CR; drug-extract ratio 4.5–8.5 : 1; Max Zeller So¨hne AG,
Romanshorn, Switzerland) was used. Placebo was identical
looking.
The treatment schedule for the double-dummy, parallel
group design was 2 tablets/once a day given with a meal in
the morning: (a) placebo (PLA) + PLA, (b) PLA + 6.5mg
Ze 450, (low dose; LD), and (c) 6.5mg Ze 450 + 6.5mg Ze
450 (high dose; HD). Treatment compliance was assessed by
a pill count of the returned medication (return of ≤25% was
considered compliant).
2.4. Outcome Measures. All assessments were done at base-
line (visit 1), optionally 6 weeks later (visit 2), and 12 weeks
later (visit 3). The severity of menopausal symptoms was
assessed at each visit using a modified total KMI score [24,
32–34]. Subitems of this index focused on the neurovegeta-
tive symptoms: a 10-item questionnaire of single symptoms
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whose severity ranged from 0 to 3 (none, mild, moderate,
and severe). Score values were multiplied by weighting
factors: hot flushes (×4), sweating (×2), insomnia (×2),
nervousness/irritability (×2), depressive events/melancholy
(×1), vertigo (×1), concentration weakness (×1), joint pain
(×1), headache (×1), and palpitations (×1). For this study,
the total KMI equalled the sum of the multiplied subitem
scores (maximum = 48) and was classified as mild (KMI ≤
20), moderate (KMI = 21–35), or severe (KMI > 35) [32].
The general quality of life (QoL) was assessed by the
visual analog scale (VAS). Using a 100mm printed line,
patients checked oﬀ how they evaluated their status (0mm =
“best possible quality of life due to health condition”;
100mm = “worst possible quality of life due to health
condition”).
At all visits, routine hematological and clinical-chemical
laboratory tests were performed. Thyroid hormones
(T3, T4), thyroid-stimulating hormone (TSH), follicle-
stimulating (FSH), luteinizing hormone (LH) and estradiol
(E2), pregnancy test, and urinalysis were performed only at
baseline.
The primary endpoint was the diﬀerence in the total KMI
between both verum groups (HD and LD) and PLA at the
end of therapy (week 12), stratified by individual baseline
scores in an intention-to-treat (ITT) analysis (patients
treated with study medication and with at least one eﬃcacy
assessment after baseline). Secondary endpoints were (1)
the analysis for each subitem of the KMI; (2) analysis of
treatment responders (patients with a reduction of ≥50% of
the total KMI); (3) a QoL analysis; (4) safety assessment.
2.5. Statistical Analysis. Within each clinical site involved
the allocation of the randomised treatment was sequential.
The random code was supplied by an external provider,
using a validated random program (Mathematica, Wolfram
Research). Randomization was provided in blocks of six to
assure balanced allocation of treatments. Each of the study
centres received their own randomization list according to
which patients were allocated to the treatment groups.
Responsible for all statistical aspects, regarding design
and analysis of the study, was the Department of Medical
Information Technology, University of Giessen, Germany.
Data management was done by Brunner and Hess,
Zurich, Switzerland. Data were entered in duplicate and
independently by suitably trained personnel at a statistical
institute, who were blinded with respect of treatment group
allocation.
Based on KMI data from previous clinical trials, sample
size was conservatively estimated as n = 60 patients/group.
Assuming an alpha-error = 0.05, mean KMI scores (SD)
of 27(15) and 18(15) in the placebo and verum groups,
respectively, an anticipated 10% drop-out rate and using the
two-sidedMann-Whitney test, a power (1−β) of >90% could
be expected (G∗Power software, University of Duesseldorf,
Germany). A predefined hierarchical statistical design was
used. Hierarchically sequenced null hypotheses were that the
medians between treatment groups at the end of treatment
would be the same, stratified by individual baseline scores:
H01 : PLA versus HD; H02 : PLA versus LD; H03 : LD versus
HD. The respective alternative hypotheses (HA1 to HA3)
stated that the medians would be diﬀerent. Comparisons
were performed by the stratified non-parametric Wilcoxon-
Mann-Whitney test (α = 0.05, 2-sided, StatXact, Version
9) to test the hypotheses with the following hierarchical-
sequentially rejecting procedure: Step 1: H01 versus HA1;
Step 2: H02 versus HA2; Step 3: H03 versus HA3. The test
procedure was terminated once a null hypothesis could not
be rejected. This hierarchical statistical design was used as
a method to control type I error for multiple comparisons.
Therefore, there was no need to adjust P values for multiple
comparisons for the 3-step testing. Responder analysis (for
total KMI) was done using the same hierarchical sequence by
Pearson’s Chi-square test. For patients terminating participa-
tion prematurely at the interim visit, all available eﬃcacy data
were treated according to the principle of last observation
carried forward (LOCF).
3. Results
Of the 232 patients originally referred to the clinics, 52
failed the selection criteria. A total of 180 patients were
randomized. Their mean age was 51.7 years and mean
BMI (Body Mass Index) was 25.2 kg/m2 when entering the
study. Safety and ITT populations comprised n = 177
and n = 166 patients, respectively (Figure 1). The majority
of patients in the ITT population (n = 85, 51.2%) were
in the early postmenopausal stage (less than 5 years since
last menstruation); fewer patients (n = 43, 25.9%) were
in the late postmenopausal (more than 5 years since last
menstruation) or premenopausal stage (n = 38, 22.9%).
A similar categorization was obtained when threshold FSH
concentration of 40mIU/mL was used. Smoking habits did
not diﬀer between the treatment groups (Table 1). Severity
of symptoms (total KMI) ranged from mild (n = 29, 17.5%)
to moderate (n = 109, 65.7%) to severe (n = 28, 16.9%).
There were no significant diﬀerences between the treatment
groups in any of the demographic parameters or for baseline
levels of T3, T4, TSH, FSH, LH, and E2.
Concerning the primary endpoint verum was superior
to placebo in reducing the total KMI score in a dose-
dependent manner (Table 2, Figure 2). Regarding KMI sub-
items, a significant reduction in each item was seen only
with the HD group. The clinical relevance was the strongest
for vasomotor subitems (e.g., hot flushes, sweating), less
for psychological/vegetative sub-items (e.g., insomnia, ner-
vousness/irritability, and depressive events/melancholy) and
the smallest for somatic symptoms (joint pain), although
significant (Table 3).
Treatment eﬀect size at the end of study (week 12)
was dependent on the baseline symptom severity (Table 4).
For patients with initially mild (total KMI ≤ 20) and
moderate symptoms (20 < total KMI ≤ 35), average KMI
scores decreased from baseline values significantly and in a
dose-dependent manner by 5.4 (8.3 SD) and 9.6 (11.5 SD)
score points in the LD group and by 10.5 (4.4 SD) and
17.8 (8.6 SD) score points in the HD group. This contrasts
to the average KMI scores in the PLA group that even
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Table 1: Demographic details: mean (SD), ITT population.
n Placebo n Low dose n High dose P value1
Age (years) 54 50.5 (7.0) 57 52.0 (6.3) 55 52.8 (6.0) 0.168
Weight (kg) 54 67.7 (11.6) 57 70.5 (13.0) 55 68.3 (12.2) 0.433
BMI (kg/m2) 54 24.9 (4.3) 57 25.6 (5.1) 55 25.0 (3.9) 0.634
Height (cm) 54 164.9 (5.1) 57 166.3 (7.1) 55 165.2 (7.4) 0.537
KMI (points) 54 27.3 (6.5) 57 28.1 (6.9) 55 28.4 (8.0) 0.692
QoL (mm) 54 37.2 (15.6) 57 31.2 (15.9) 55 34.7 (17.6) 0.150
Premenopausal (n) 54 15 57 12 55 11
0.8032Early postmenopausal (n) 54 27 57 28 55 30
Late postmenopausal (n) 54 12 57 17 55 14
Baseline FSH ≤ 40mIU/mL (n) 54 21 57 22 55 15
0.3332Baseline FSH > 40mIU/mL (n) 54 22 57 26 55 33
Baseline FSH unknown 54 11 57 9 55 7
Baseline KMI ≤ 20 54 9 57 10 55 10
0.4542Baseline KMI 21–35 54 36 57 41 55 32
Baseline KMI > 35 54 9 57 6 55 13
Nonsmoker (n) 54 41 57 44 55 39
0.5753
Occasional smoker (n) 54 3 57 0 55 4
Moderate smoker (n) 54 6 57 7 55 7
Heavy smoker (n) 54 4 57 6 55 5
1Analysis of variance, 2Chi-square test, 3Fisher’s exact test.
High dose
Excluded
Allocation
Analysis
Patients screened
n = 232
Screening failures, n = 52
Dropouts
n = 3
No followup for eﬃcacy
n = 11
Low dose
n = 5 n = 557
Placebo
n = 54
Followup
Patients randomized
n = 180
Safety population
n = 177
Intention to treat
(ITT)
n = 166
Figure 1: CONSORT diagram of the disposition of participants.
increased from baseline values by 12.2 (4.7 SD) (initially mild
symptoms) and 0.6 (7.8 SD) (initially moderate symptoms)
score points. For patients with initially severe symptoms
(total KMI > 35), average scores decreased by 4.8 (8.5
SD) (PLA), 5.8 (12.0 SD) (LD), and 20.1 (9.5) (HD) score
points. However, only for the HD group could a significant
diﬀerence versus the PLA group be demonstrated.
For premenopausal patients, only the HD showed a
significant (P < 0.001) decrease in average total KMI
scores compared to the PLA group (20.9 (7.6 SD) versus
1.1 (7.8 SD) score points, resp.). In patients in the early
and late postmenopausal states, comparable magnitudes
of eﬀects of Ze 450 treatments were observed: LD and
HD treatments in early postmenopausal women decreased
KMI by 11.0 (11.2 SD) and 17.2 (9.7 SD) score points,
respectively, whereas PLA increased KMI by 3.3 (7.9 SD)
score points. In late postmenopausal women, LD and HD
treatment decreased KMI by 10.2 (11.2 SD) and 13.6 (5.8 SD)
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Table 2: Intention to treat analysis: total KMI after 12 weeks of treatment (n = 166).
Treatment n
Baseline End of study Absolute diﬀerences Hierarchical test procedure∗
Mean (SD) 95% CI Mean (SD) 95% CI Mean (SD) 95% CI Step 1 Step 2 Step 3
Placebo 54 27.30 (6.5) 25.53–29.06 28.94 (7.6) 26.87–31.02 1.65 (9.0) −0.80–4.10 Reference Reference
Low dose 57 28.12 (6.9) 26.28–29.96 19.65 (13.1) 16.17–23.13 −8.47 (11.0) −11.39 to −5.55 P = 0.0003 Reference
High dose 55 28.44 (8.0) 26.28–30.60 11.44 (9.1) 8.98–13.90 −17.00 (8.7) −19.35 to −14.65 P < 0.0001 P = 0.0057
∗
According to two-sided Mann-Whitney test stratified to individual baseline scores; 95% CI: 95% confidence interval; SD: standard deviation; n: number of
patients.
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Figure 2: Total KMI (a) at baseline and (b) after 12 weeks of treatment (ITT population, n = 166) with PLA, LD, and HD. Circles denote
outliers. Two-sided Mann-Whitney test stratified to baseline scores.
score points, respectively, whereas PLA increased KMI by
1.5 (12.1 SD) score points. However, in contrast to the
early postmenopausal subgroup, in the late postmenopausal
subgroup no superiority for the HD over the LD group could
be established.
With respect to the secondary endpoints, the responder
rate for ≥50% reduction in total KMI increased from 7.4%
in the PLA group to 40.4% in the LD group (P < 0.001) and
increased further to 69.1% in the HD group. The latter was
significantly higher than in the PLA group (P < 0.001) or the
LD group (P = 0.002).
Corresponding to the reduction in symptom severity, the
QoL VAS increased dose-dependently (Figure 3). Changes in
menopausal symptoms and QoL were inversely correlated.
As to safety no serious, but 21 nonserious adverse events
(AE) occurred in 20 patients: 9 of which were possibly
treatment related (5 PLA, 2 LD, and 2 HD group), five were
unlikely or not related to the study medication, and the
relationship was assessed as unknown for seven. Among the
nine possibly study-related AEs, five were of a gastrointestinal
nature, a known AE of Ze 450. The frequency of possibly
related AEs was higher in the placebo group. Laboratory
assessments revealed no clinically significant changes, except
for three patients (one from each group) with elevated liver
enzyme values. Two were likely caused by excessive alcohol
consumption, while the third remained undefined. These
three AEs were not clustered in one specific treatment group;
but they were equally distributed among the three groups.
No safety concerns were raised based on the monitoring of
vital signs, physical examination, and laboratory values from
the beginning to the end of the study.
4. Discussion
Our study demonstrated that the CR extract administered for
12 weeks decreased significantly, and in a dose-dependent
manner, the severity of climacteric symptoms in the total
KMI. This was predominantly seen in single subitems
especially for vasomotor as well as for some psychological
symptoms. Furthermore, the administration of CR extract
over 12 weeks improved general QoL and was safe.
The strengths of the current trial are as follows. (a) It
analysed one of the unanswered questions in the nonhor-
monal treatment of menopausal complaints with extracts
from CR—the dose-dependency. This was done in a suitable
methodological manner with the high internal validity
of the 3-arm RCT. Blinding was achieved by applying a
double-blind, double-dummy setting in order to avoid any
unblinding bias.
(b) A subgroup analysis showed that both the LD
and HD demonstrated, in a dose-dependent manner, a
significantly larger eﬀect than placebo in patients with mild
and moderate symptom severity. For patients with severe
symptoms, however, only the high dose (13.0mg) of Ze 450
was eﬀective. Compared to the placebo and LD groups, only
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Table 4: Change in symptom severity as assessed by total KMI in patient subgroups.
Treatment n
Baseline End of study Absolute diﬀerences Hierarchical test procedure∗
Mean (SD) Mean Mean (SD) 95% CI Step 1 Step 2 Step 3
Baseline KMI ≤ 20
Placebo 9 17.7 (2.2) 29.9 (4.3) 12.2 (4.7) 8.58–15.86 Ref. Ref.
Low dose 10 18.4 (2.7) 13.0 (8.5) −5.4 (8.3) −11.35 to −0.55 P < 0.001 Ref.
High dose 10 17.3 (3.0) 6.8 (5.0) −10.5 (4.4) −13.65 to −7.35 P < 0.001 NS
21 ≤ baseline KMI ≤ 35
Placebo 36 27.2 (3.6) 27.8 (8.1) 0.6 (7.8) −2.01–3.23 Ref. Ref.
Low dose 41 28.7 (4.1) 19.1 (12.6) −9.6 (11.5) −13.23 to −5.99 P < 0.001 Ref.
High dose 32 27.5 (4.0) 9.7 (7.6) −17.8 (8.6) −20.87 to −14.70 P < 0.001 P = 0.004
Baseline KMI > 35
Placebo 9 37.2 (1.1) 32.4 (7.7) −4.8 (8.5) −11.27–1.72 Ref. Ref.
Low dose 6 40.5 (3.5) 34.7 (13.0) −5.8 (12.0) −18.38–6.71 NS Ref.
High dose 13 39.3 (2.4) 19.2 (10.7) −20.1 (9.5) −25.83 to −14.33 P = 0.001 P = 0.022∗∗
Premenopausal
Placebo 15 29.5 (6.4) 28.4 (8.9) −1.1 (7.8) −5.43–3.16 Ref. Ref.
Low dose 12 25.5 (8.6) 25.3 (12.3) −0.2 (5.4) −3.62–3.29 NS Ref.
High dose 11 27.6 (9.5) 6.7 (6.3) −20.9 (7.6) −26.00 to −15.82 P < 0.001 P = 0.001∗∗
Early postmenopausal
Placebo 27 26.4 (6.8) 29.6 (6.7) 3.3 (7.9) 0.13–6.39 Ref. Ref.
Low dose 28 27.5 (6.0) 16.6 (12.7) −11.0 (11.2) −15.31 to −6.62 P < 0.001 Ref.
High dose 30 28.4 (7.2) 11.2 (9.0) −17.2 (9.7) −20.81 to −13.53 P < 0.001 P = 0.039
Late postmenopausal
Placebo 12 26.6 (5.6) 28.1 (8.3) 1.5 (12.1) −6.21–9.21 Ref. Ref.
Low dose 17 30.9 (6.5) 20.7 (13.6) −10.2 (11.2) −15.99 to −4.48 P = 0.006 Ref.
High dose 14 29.2 (8.9) 15.6 (9.8) −13.6 (5.8) −16.91 to −10.24 P = 0.001 NS
∗
Two-sided Mann-Whitney test stratified to baseline values; Ref.: reference; descriptive P values.
∗∗Not applicable due to hierarchical design; NS: not significant; SD: standard deviation; 95% CI: 95% confidence interval; n: number of patients.
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Figure 3: QoL assessment by VAS (a) at baseline and (b) after 12 weeks of treatment (ITT population, n = 166) with PLA, LD, and HD.
Circles denote outliers. Two-sided Mann-Whitney test stratified to baseline scores.
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the high dose reduced significantly the symptom score in
patients at all menopausal stages; the LD was superior to
placebo only in the early and late postmenopausal stage.
Nonetheless, there are some limitations. (a) Although
the study duration was 3 months, a longer duration of
6–12 months would better meet the necessary long-term
treatment of most women. This will be the subject of a
future trial. (b) The question which menopause scale should
be administered is an ongoing discussion. Although the
comparison of the Menopause Rating Scale (MRS) with
the KMI produced a high correlation of raw scores, the
MRS, especially in its second version (MRS-II), is somehow
favoured today [35, 36]. This might be due to its better
appropriateness for factor analysis of symptom clusters
and QoL measurements. Nonetheless, it is known that CR
extracts are most eﬀective for vasomotor symptoms therefore
it seemed appropriate to use the KMI [28, 31]. Additionally,
we tried to overcome this shortcoming with analysing the
single symptoms next to total KMI score, giving a subgroup
analysis and rating general QoL with the VAS.
The placebo response might have been low in the
present study. However, also in other clinical trials in
postmenopausal women, with a small number of visits, no
reduction of the KMI was observed with placebo treatment
[36, 37] as it was the case in the present study. On the
other hand, higher placebo eﬀects were observed in trials,
where more patients visits had been performed (such as in
[34]). This suggests that the study design might influence the
placebo response.
The results of our current study partly confirm previous
studies with other CR extracts [20, 23–26]. The age and
BMI distribution of the patients are comparable to several
previously conducted clinical studies with extracts from CR.
Nevertheless, the study population is still small and may
give predictions at best for middle-European women without
heavy overweight. However, Liske et al. [25] have shown
that two doses of an isopropanolic aqueous CR extract given
for 24 weeks reduced significantly the symptom severity
as assessed by KMI to a similar extent. In both treatment
groups, total KMI decreased by about 50% from baseline
scores of 30.5 (low dose) and 31 (high dose) to scores less
than 15 in 70% and 72% of the patients, respectively. The
responder rates were comparable to our study, where the rate
of patients with at least a 50% decrease in total KMI was
69.1% in the HD group. In contrast to the study of Liske
et al., however, we could clearly demonstrate for the first
time a dose-dependent eﬀect of a CR extract. The eﬃcacy
of other CR extracts was further shown by Osmers et al. [23]
using a fixed dose of an isopropanolic extract and a placebo
treatment during a 12-week period. In a further study of
the same extract continued for 52 weeks, the eﬀect on the
number and intensity of hot flushes was confirmed [38] and,
in addition, overall tolerability and endometrial safety were
demonstrated. On the other hand, after a short-term, 4-week
treatment in patients suﬀering from breast cancer, a similar
CR extract demonstrated no superior eﬀect when compared
to placebo [39]. However, the extract used in the latter
study was not suﬃciently characterized and the duration
of treatment was shorter than in previous studies [20, 23–
26] that have demonstrated a significant reduction in the
number and intensity of hot flushes. Additionally, the dose-
eﬀect relationship was not investigated. This underscores
the diﬃculties in comparing clinical results between studies
using diﬀerent extracts with potentially diﬀerent spectra of
pharmacologically active constituents.
Whether the treatment eﬀects of Ze 450 can be main-
tained for longer treatment periods is a subject for further
research. Reported AEs did not raise safety concerns.
In conclusion, the CR extract, Ze 450, appears to be an
eﬀective and well-tolerated nonhormonal alternative to HRT
for symptom relief in menopausal women.
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